

Blankart, C., R., A. Foster, & V. Mor 2018. The Effect of Political Control on Financial Performance, Structure, and Outcomes of US Nursing Homes. *Health Services Research*, accepted.

Dams, F., J. L. Gonzalez Rodriguez, K. L. Cheung, B. F. Wijnen, & M. Hilgsmann 2018. Relevance of barriers and facilitators in the use of health technology assessment in Colombia. *Journal of medical economics*, 21(5), 510-517.

Blankart, C., R., A. Foster, & V. Mor 2017. The Effect of Political Control on Financial Performance and Structure of US Nursing Homes. *Acad Manage Proc* 2017.

Hatz, M. H. M., Sonnenschein, T., & Blankart, C. R. 2017. The PMA Scale: A Measure of Physicians' Motivation to Adopt Medical Devices. *Value in Health*, 20(4): 533-541.

Varabyova, Y., Blankart, C. R., Greer, A. L., & Schreyögg, J. 2017. The determinants of medical technology adoption in different decisional systems: A systematic literature review. *Health Policy*, 121(3): 230-242.

Hatz, M. H. M., Schreyögg, J., Torbica, A., Boriani, G., & Blankart, C. R. B. 2017. Adoption Decisions for Medical Devices in the Field of Cardiology: Results from a European Survey. *Health Economics*, 26(S1): 124-144.

Varabyova, Y., Blankart, C. R., & Schreyögg, J. 2017. The Role of Learning in Health Technology Assessments: An Empirical Assessment of Endovascular Aneurysm Repairs in German Hospitals. *Health Economics*, 26(S1): 93-108.

Sachweh, A., von Kodolitsch, Y., Kölbel, T., Larena-Avellaneda, A., Wipper, S., Bernhardt, A. M., Girdauskas, E., Detter, C., Reichenspurner, H., Blankart, C. R., & Debus, E. S. 2017. I-SWOT as instrument to individually optimize therapy of thoracoabdominal aortic aneurysms. *Gefäßchirurgie*, 22(1): 8-16.

Varabyova, Y., Blankart, C. R., & Schreyögg, J. 2017. Erratum to: Using nonparametric conditional approach to integrate quality into efficiency analysis: empirical evidence from cardiology departments. *Health Care Manag Sci*, 20(4): 577. Varabyova, Y., Blankart, C. R., & Schreyögg, J. 2017. Using nonparametric conditional approach to integrate quality into efficiency analysis: empirical evidence from cardiology departments. *Health Care Manag Sci*, 20(4): 565-576. Blankart, C. R., & Stargardt, T. 2017. Preferred supplier contracts in post-patent prescription drug markets. *Health Care Manag Sci*, 20(3): 419-432. Varabyova, Y., Blankart, C. R., Torbica, A., & Schreyögg, J. 2017. Comparing the Efficiency of Hospitals in Italy and Germany: Nonparametric Conditional Approach Based on Partial Frontier. *Health Care Manag Sci*, 20(3): 379-394. Schlage, V., & Blankart, C. R. 2016. Does Direct-care Staffing Impact Nursing Home Outcomes? A Systematic Review. *Die Unternehmung*, 70(3): 291-318.

Blankart, C. R., Emanuel, E. J., Bekelman, J. E., & International Consortium for End-of-Life, R. 2016. Characteristics of Patients Dying With Cancer in Developed Countries--Reply. *JAMA*, 315(24), 2732.

Blankart, C. R., Milstein, R., Rybczynski, M., Schüler, H., & von Kodolitsch, Y. 2016. Economic and care considerations of Marfan syndrome. *Expert Review of Pharmacoeconomics & Outcomes Research*, 16(5): 591-598.

Milstein, R., & Blankart, C. R. 2016. The Health Care Strengthening Act: the next level of integrated care in Germany. *Health Policy*, 120(5): 445-451.

Bekelman, J. E., Halpern, S. D., Blankart, C. R., Bynum, J. P., Cohen, J., Fowler, R., Kaasa, S., Kwietniewski, L., Melberg, H. O., Onwuteaka-Philipsen, B., Oosterveld-Vlug, M., Pring, A., Schreyögg, J., Ulrich, C. M., Verne, J., Wunsch, H., Emanuel, E. J., & International Consortium for End-of-Life, R. 2016. Comparison of Site of Death,

Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries. *JAMA*, 315(3): 272-283.

Frey, S., Blankart, C. R., & Stargardt, T. 2016. Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature. *Pharmacoeconomics*, 34(5): 479-498.

von Kodolitsch, Y., Blankart, C. R., Vogler, M., Kallenbach, K., & Robinson, P. N. 2015. [Genetics and prevention of genetic aortic syndromes (GAS) and of the Marfan syndrome]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*, 58(2): 146-153.

Ciani, O., Wilcher, B., Blankart, C. R., Hatz, M., Rupel, V. P., Erker, R. S., Varabyova, Y., & Taylor, R. S. 2015. Health technology assessment of medical devices: a survey of non-European union agencies. *Int J Technol Assess Health Care*, 31(3): 154-165.

Achelrod, D., Blankart, C. R., Linder, R., von Kodolitsch, Y., & Stargardt, T. 2014. The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study. *Orphanet J Rare Dis*, 9: 90.

Blankart, C. R., Koch, T., Linder, R., Verheyen, F., Schreyögg, J., & Stargardt, T. 2013. Cost of illness and economic burden of chronic lymphocytic leukemia. *Orphanet J Rare Dis*, 8: 32.

Blankart, C. R. 2012. Does healthcare infrastructure have an impact on delay in diagnosis and survival? *Health Policy*, 105(2-3): 128-137.

Blankart, C. R., Stargardt, T., & Schreyögg, J. 2011. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia. *Pharmacoeconomics*, 29(1): 63-82.

Blankart, R., Schreyögg, J., & Busse, R. 2008. Performance of reimbursement schemes in valuation of technologies: the example of magnetic resonance imaging. *Technol Health Care*, 16(3): 171-182.